Jingchuan Guo
Overview
Explore the profile of Jingchuan Guo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Radwan R, Lee Y, Kotecha P, Wright D, Hernandez I, Ramon R, et al.
Diabetes Obes Metab
. 2025 Mar;
PMID: 40035205
Aims: To characterize trends in the initiation of newer anti-obesity medications (AOMs) and determine factors associated with their use among obese/overweight populations. Materials And Methods: This study utilized electronic health...
2.
Tang H, Lu Y, Donahoo W, Westen S, Chen Y, Bian J, et al.
Ann Intern Med
. 2025 Feb;
PMID: 39993315
Background: Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential antidepressant effects, population studies yield inconsistent results. Objective: To compare the risk for depression in older adults with type 2...
3.
Radwan R, Lee Y, Kotecha P, Wright D, Hernandez I, Ramon R, et al.
medRxiv
. 2025 Feb;
PMID: 39974110
Aims: To characterize trends in the initiation of newer anti-obesity medications (AOMs) and determine factors associated with their use among obese/overweight populations. Materials And Methods: This retrospective study utilized electronic...
4.
Yang L, Guo J, Kane-Gill S, Gabriel N, Empey K, Suh K, et al.
Pharmacoepidemiol Drug Saf
. 2025 Jan;
34(2):e70098.
PMID: 39842818
Purpose: To characterize trajectories of nephrotoxic potential (NxP) drug use among older adults with Type 2 Diabetes (T2D) treated with SGLT2is and identify associated patient characteristics. Methods: Using 2012-2019 Medicare...
5.
Tang H, Zhang B, Lu Y, Donahoo W, Ospina N, Kotecha P, et al.
Diabetes Obes Metab
. 2024 Dec;
27(3):1444-1455.
PMID: 39723481
Aim: To comprehensively evaluate the benefits and risks of glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase 4 inhibitors (DPP4i), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). Materials And Methods: A systematic...
6.
Cho H, Kalina E, Wu J, Cook R, Salloum R, Liu Y, et al.
J Clin Nurs
. 2024 Nov;
34(2):422-429.
PMID: 39603980
Background: People with HIV have a higher risk of developing non-AIDS-defining cancers in older age, leading to a significant population living with two conditions, HIV and cancer. There is an...
7.
Tang H, Germinal K, Milfort A, Chen W, Chang S, Huang W, et al.
BMC Cardiovasc Disord
. 2024 Nov;
24(1):666.
PMID: 39578732
Background: Evidence for the efficacy of pharmacological therapies for heart failure with reduced ejection fraction (HFrEF) is growing. However, there is no consensus on the most effective treatment for HFrEF....
8.
Chang S, Cabrera R, Heo J, Park C, Guo J, Park H
Clin Pharmacol Ther
. 2024 Nov;
PMID: 39489881
The association between direct-acting antiviral (DAA) treatment and hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is currently unclear. Hence, we aim to assess the association between DAA treatment and mortality...
9.
Chen W, Li Y, Chen A, Allen J, Guo Y, Bilello L, et al.
J Manag Care Spec Pharm
. 2024 Oct;
30(11):1298-1307.
PMID: 39471265
Background: Two classes of newer glucose-lowering drugs (GLDs), sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, improve cardiovascular and renal outcomes among patients with type 2 diabetes (T2D). However, racial...
10.
A fair individualized polysocial risk score for identifying increased social risk in type 2 diabetes
Huang Y, Guo J, Donahoo W, Lee Y, Fan Z, Lu Y, et al.
Nat Commun
. 2024 Oct;
15(1):8653.
PMID: 39369018
Racial and ethnic minorities bear a disproportionate burden of type 2 diabetes (T2D) and its complications, with social determinants of health (SDoH) recognized as key drivers of these disparities. Implementing...